Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer

Inclusion Criteria: Patients with advanced OSCC who received NACI before surgery * Confirmation of primary OSCC by two experienced pathologists; * Clinical stage III/ IVA (cT1-2/cN1-2/M0 or cT3-4a/cN0-2/M0) according to the 8th Edition of American Joint Committee on Cancer (AJCC) guideline; * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; * No prior anti-cancer therapy; * Locally resectable advanced tumor evaluated by a head and neck surgeon. Advanced OSCC patients who only received surgery * A histopathologic diagnosis of primary OSCC; * A clinical stage of III/IVA (AJCC, 8th edition); * An ECOG performance status of 0 to 1. Exclusion Criteria: Patients with advanced OSCC who received NACI before surgery * Patients with other pathological types, without NACI or Surgery; * Incomplete pre-treatment data; * Lost to follow up were excluded from the study. Advanced OSCC patients who only received surgery * Patients who had received other therapies targeting the head and neck region before the surgery or those with evidence of recurrence or metastasis, as assessed by physical examination reports or imaging studies before surgery * Lost to follow up.